BiondVax Pharmaceuticals Ltd. Announces Pricing of U.S. Initial Public Offering of 1,910,000 ADSs and Warrants to Purchase 1,...
11 Maio 2015 - 9:12PM
BiondVax Pharmaceuticals Ltd (Nasdaq:BVXV)
(Nasdaq:BVXVW), a clinical stage biopharmaceutical company focused
on developing and commercializing immunomodulation therapies for
infectious diseases, today announced the pricing of its initial
public offering in the United States of 1,910,000 American
Depositary Shares (ADSs), each ADS representing 40 of its ordinary
shares, and warrants to purchase 1,910,000 ADSs at an offering
price of $5.00 per ADS and $0.01 per warrant. The warrants
will have a per ADS exercise price of $6.25, are exercisable
immediately and will expire on May 15, 2020.
The gross proceeds to BiondVax from this offering are
expected to be $9,550,000 before deducting underwriting
discounts and commissions and other estimated offering
expenses. BiondVax has granted the underwriter a 45-day
option to purchase up to an additional 286,500 ADSs and/or warrants
to purchase 286,500 ADSs to cover over-allotments, if any.
The ADSs and warrants are scheduled to begin trading on
The NASDAQ Capital Market on May 12, 2015 under
the symbol "BVXV" and "BVXVW," respectively. The offering is
expected to close on May 15, 2015, subject to customary
closing conditions.
Aegis Capital Corp. is acting as sole book-running
manager for the offering.
A registration statement relating to these securities has been
declared effective by the Securities and Exchange
Commission on May 11, 2015.
This offering is being made only by means of a
prospectus. Copies of the prospectus relating to this
offering may be obtained by contacting Aegis Capital Corp.,
Prospectus Department, 810 Seventh Avenue, 18th
Floor, New York, NY 10019, telephone: 212-813-1010,
e-mail: prospectus@aegiscap.com. Investors may also obtain
these documents at no cost by visiting the SEC's website at
http://www.sec.gov.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About BiondVax
BiondVax is an innovative biopharmaceutical company developing a
universal flu vaccine, designed to provide multi-season and
multi-strain protection against most human influenza virus strains,
including both seasonal and pandemic flu strains.
BiondVax's technology utilizes a unique, proprietary combination
of conserved and common peptides from influenza virus proteins to
activate both arms of the immune system for a cross-protecting and
long-lasting effect. Forward Looking
Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements involve certain risks and uncertainties, including,
among others, risks impacting the ability of BiondVax
Pharmaceuticals Ltd. to complete any public offering of its
securities because of general market conditions or other factors
and risks that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals
Ltd. More detailed information about the risks and
uncertainties affecting BiondVax Pharmaceuticals Ltd. is
contained under the heading "Risk Factors" in BiondVax
Pharmaceuticals Ltd.'s registration statement on Form F-1
filed with the SEC, which is available on
the SEC's web site, www.sec.gov. BiondVax
Pharmaceuticals Ltd. undertakes no obligation to update or
revise any forward-looking statements.
CONTACT: Company Contact
Ron Babecoff, CEO
babecoff@biondvax.com
Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
1 646 201 9246
biondvax@gkir.com
BiondVax Pharmaceuticals (NASDAQ:BVXVW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
BiondVax Pharmaceuticals (NASDAQ:BVXVW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024